Additionally, our laboratory as well as others, have shown that agonism of the β2AR elicits ROS generation5,6,8–12,50,51, and together, these data suggest that chronic use of β2AR agonists in these pulmonary diseases can lead to a significantly higher oxidative load. Here, ADRB2 is linked to lung disorder.